NeuMoDx CEO and leadership

Jeff is the founding CEO of NeuMoDx Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.

Dan serves as the Chief Commercial Officer at NeuMoDx Molecular where he is responsible for building and leading the infrastructure to market and support the NeuMoDx Molecular solutions. Previously, Dan was with Abbott Diagnostics for over 25 years serving in various commercial leadership roles including Sales, Marketing, Enterprise Account Management and International General Management. He has a proven track record of hiring, developing and leading top performing commercial organizations.

Dan received his Bachelors of Business Degree from the University of Wisconsin - Whitewater and MBA from Loyola University-Chicago.

Jeff is the founding CEO of NeuMoDx Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.

Jeff is the founding CEO of NeuMoDx Molecular. Previously, he had been President and CEO of Accuri Cytometers, a life science instrument and clinical diagnostic company, from January 2010 until its sale to Becton, Dickinson and Company (NYSE: BDX) for $205M in March 2011. During his tenure at Accuri, Jeff oversaw year-over-year revenue growth of 65%, the development of a clinical system, and the achievement of positive cash flow. Prior to Accuri, he had been President and CEO of HandyLab, a molecular diagnostic company, since 2004. At HandyLab, Jeff led the growth and venture financing of the company, ultimately resulting in its sale for $275M in November 2009. Prior to HandyLab, Jeff was President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997. He led Genomic Solutions through a period of rapid growth culminating in an IPO on NASDAQ in 2000 and merger with Harvard Biosciences, Inc. in late 2002. Prior to Genomic Solutions, Jeff held executive and management level positions in several bioscience companies, including IRIS and Boehringer Mannheim.Jeff received a BS in Biology from Alma College and a MBA from the University of Michigan.